IN THIS ISSUE
Highlighted research articles...............................vi

NEWS IN BRIEF
Important news stories affecting the community..................97

NEWS IN DEPTH
Q&A: Tom Curran on Translational Research .............99
Finding New Uses for Existing Medications .............100
Cancer Centers Work to Optimize Pipelines .............101

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature...........102

ONLINE
For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews.

IN THE SPOTLIGHT
New Roles Opined for OPCML..........................115
S.Y. Wu and A.K. Saad

Commentary on McKie et al., p. 156

Prospective
Cancers of the Colon and Rectum: Identical or Fraternal Twins? ............117
T.S. Heng, J.W. Clark, and K.M. Haigis

RESEARCH BRIEFS
J. Sun, D.N. Tong, T. Fu, and P. Sharma

Précis: Latency-associated peptide is an accurate surrogate marker of regulatory T cells that will facilitate functional studies of immunotherapy.

Inherited Variation at Chromosome 12p13.33, Including RAD52, Influences the Risk of Squamous Cell Lung Carcinoma ..................131

Précis: A pathway-based analysis of a genome-wide association study identifies a squamous cell lung carcinoma susceptibility locus harboring the RAD52 gene.
Précis: Overexpression of the ubiquitin ligase A20 is a mechanism of resistance to TRAIL pathway–targeted therapy in glioblastoma.

The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer.

Précis: OPCML binds the extracellular domains of specific receptor tyrosine kinases to induce their endocytic internalization and proteosomal degradation.

Correction

Correction: An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway.